Overview
ALLO market data
Price History
ALLO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ALLO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration SeenBenzinga · Jul 15, 2026, 12:33 PM
8-K filing — Allogene Therapeutics, Inc. (ALLO)SEC EDGAR · Jun 22, 2026, 8:05 PM
Allogene Therapeutics' Dr. David Chang, M.D., Ph.D. To Transition From President and Chief Executive Officer, Effective On June 30, 2026; Co. Elects Zachary Roberts, M.D., Ph.D. As President And Chief Executive Officer, Effective July 1, 2026Benzinga · May 28, 2026, 9:28 PM
Allogene Therapeutics Q1 2026 Earnings Call TranscriptBenzinga · May 13, 2026, 10:12 PM
Allogene Therapeutics Enters Termination Agreement With Overland Therapeutics On May 12, 2026; Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026; No Termination Payments Made In Connection With Termination Agreement; To Hold About 3% Of Overland Equity After Surrendering Portion For No ConsiderationBenzinga · May 13, 2026, 8:49 PM
Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) EstimateBenzinga · May 13, 2026, 8:03 PM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM